NASDAQ:XRTX XORTX Therapeutics (XRTX) Stock Price, News & Analysis $0.90 -0.02 (-1.65%) As of 03:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About XORTX Therapeutics Stock (NASDAQ:XRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XORTX Therapeutics alerts:Sign Up Key Stats Today's Range$0.87▼$0.9450-Day Range$0.91▼$2.4852-Week Range$0.83▼$3.60Volume20,598 shsAverage Volume587,481 shsMarket Capitalization$1.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview XORTX Therapeutics Inc. (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases. XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function. The company has also described additional programs targeting diabetic kidney disease and other diseases in which elevated uric acid and xanthine oxidase activity may contribute to tissue damage. Based in Calgary, Alberta, XORTX conducts research and development activities in North America and works to advance its pipeline through clinical development and regulatory evaluation. Its programs remain investigational and are subject to clinical, regulatory and commercial development requirements.AI Generated. May Contain Errors. Read More XORTX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreXRTX MarketRank™: 0.1987704918 of 5 starsXORTX Therapeutics scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXORTX Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXORTX Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about XORTX Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XORTX Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XORTX Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXORTX Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about XORTX Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.01% of the float of XORTX Therapeutics has been sold short.Short Interest Ratio / Days to CoverXORTX Therapeutics has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XORTX Therapeutics has recently increased by 285.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldXORTX Therapeutics does not currently pay a dividend.Dividend GrowthXORTX Therapeutics does not have a long track record of dividend growth.Read more about XORTX Therapeutics' dividend. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for XRTX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows1 people have added XORTX Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XORTX Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of XORTX Therapeutics is held by insiders.Percentage Held by Institutions0.23% of the stock of XORTX Therapeutics is held by institutions.Read more about XORTX Therapeutics' insider trading history. Receive XRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XORTX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XRTX Stock News HeadlinesXORTX Therapeutics Inc XRTXOctober 16, 2026 | morningstar.comMXORTX Plans Canadian Trial Of Gout Drug XORLO To Support Future U.S. NDA Filing; Stock UpOctober 9, 2026 | rttnews.comWhy Iran May Only Be the First MoveTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.November 9 at 1:00 AM | Behind the Markets (Ad)Xortx Therapeutics Shares Rise After Company Reports Potential Partner Interest for Gout ProgramOctober 8, 2026 | finance.yahoo.comXORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for GoutOctober 8, 2026 | financialpost.comFXORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market OpportunitySeptember 19, 2026 | barrons.comXORTX Therapeutics Shares Rise 12% On IND Submission PlanSeptember 19, 2026 | rttnews.comXORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A YearSeptember 18, 2026 | rttnews.comSee More Headlines XRTX Stock Analysis - Frequently Asked Questions How have XRTX shares performed this year? XORTX Therapeutics' stock was trading at $2.81 at the beginning of the year. Since then, XRTX shares have decreased by 68.3% and is now trading at $0.8920. How were XORTX Therapeutics' earnings last quarter? XORTX Therapeutics Inc. (NASDAQ:XRTX) released its earnings results on Saturday, August, 15th. The technology company reported ($1.05) EPS for the quarter. When did XORTX Therapeutics' stock split? XORTX Therapeutics's stock reverse split on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, April 1st 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of XORTX Therapeutics? Shares of XRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/15/2026Today11/09/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (17m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 XRTX's financial health is in the Red zone, according to TradeSmith. XRTX has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:XRTX CIK1729214 Webwww.xortx.com Phone+44-23-92496000FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-137.85% Return on Assets-108.16% Debt Debt-to-Equity RatioN/A Current Ratio3.58 Quick Ratio3.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.58Miscellaneous Outstanding Shares1,817,000Free Float1,692,000Market Cap$1.59 million OptionableNot Optionable Beta0.83 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:XRTX) was last updated on 11/9/2026 by MarketBeat.com Staff. From Our PartnersTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredOne Ticker Tied to a Coming 401k ChangeAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTesla pays zero dividends but this new fund pays monthlyTesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a differen...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XORTX Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XORTX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
